Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus SULFAMETHOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM versus SULFAMETHOPRIM.
SULFACETAMIDE SODIUM vs SULFAMETHOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitively inhibits dihydropteroate synthase, blocking folic acid synthesis in susceptible bacteria.
Sulfamethoprim is a combination of sulfamethoxazole and trimethoprim. Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits bacterial dihydrofolate reductase, also blocking folic acid synthesis. This sequential blockade produces bactericidal effects.
1-2 drops of 10-30% solution into the conjunctival sac every 2-3 hours initially, tapering as infection resolves. Ointment: 0.5-inch ribbon into conjunctival sac every 3-4 hours and at bedtime.
Oral or intravenous: 800 mg sulfamethoxazole / 160 mg trimethoprim every 12 hours.
None Documented
None Documented
7-12.8 hours (prolonged in renal impairment; requires dosing adjustment in CrCl <50 mL/min).
Terminal elimination half-life: 8-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours).
Renal: 85-95% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Renal: 60-80% as unchanged drug via glomerular filtration and tubular secretion; biliary: 5-10%; fecal: <5%.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic